Craneware (LON:CRW) Full Year 2024 Results
Key Financial Results
- Revenue: US$189.3m (up 8.8% from FY 2023).
- Net income: US$11.7m (up 27% from FY 2023).
- Profit margin: 6.2% (up from 5.3% in FY 2023). The increase in margin was driven by higher revenue.
- EPS: US$0.34 (up from US$0.26 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Craneware Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 18%.
In the last 12 months, the only revenue segment was Healthcare Software contributing US$189.3m. The largest operating expense was General & Administrative costs, amounting to US$141.4m (94% of total expenses). Explore how CRW's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe.
Performance of the market in the United Kingdom.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 1 warning sign for Craneware that you need to be mindful of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:CRW
Craneware
Develops, licenses, and supports computer software for the healthcare industry in the United States.
Reasonable growth potential with proven track record.
